Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery

Cassandra Koole, Denise Wootten, John Simms, Laurence J Miller, Arthur Christopoulos, Patrick M Sexton

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that has a critical role in the regulation of glucose homeostasis, principally through the regulation of insulin secretion. The receptor system is highly complex, able to be activated by both endogenous [GLP-1(1-36)NH2, GLP-1(1-37), GLP-1(7-36)NH2, GLP-1(7-37), oxyntomodulin], and exogenous (exendin-4) peptides in addition to small-molecule allosteric agonists (compound 2 [6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline], BETP [4-(3-benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine]). Furthermore, the GLP-1R is subject to single-nucleotide polymorphic variance, resulting in amino acid changes in the receptor protein. In this study, we investigated two polymorphic variants previously reported to impact peptide-mediated receptor activity (M149) and small-molecule allostery (C333). These residues were mutated to a series of alternate amino acids, and their functionality was monitored across physiologically significant signaling pathways, including cAMP, extracellular signal-regulated kinase 1 and 2 phosphorylation, and intracellular Ca(2+) mobilization, in addition to peptide binding and cell-surface expression. We observed that residue 149 is highly sensitive to mutation, with almost all peptide responses significantly attenuated at mutated receptors. However, most reductions in activity were able to be restored by the small-molecule allosteric agonist compound 2. Conversely, mutation of residue 333 had little impact on peptide-mediated receptor activation, but this activity could not be modulated by compound 2 to the same extent as that observed at the wild-type receptor. These results provide insight into the importance of residues 149 and 333 in peptide function and highlight the complexities of allosteric modulation within this receptor system.

Original languageEnglish
Pages (from-to)52-63
Number of pages12
JournalThe Journal of pharmacology and experimental therapeutics
Volume353
Issue number1
DOIs
Publication statusPublished - Apr 2015
Externally publishedYes

Fingerprint

Amino Acid Substitution
Peptides
Glucagon-Like Peptide 1
Peptide Receptors
Oxyntomodulin
Amino Acids
Mutation
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
G-Protein-Coupled Receptors
Homeostasis
Nucleotides
Phosphorylation
Insulin
Glucose
Glucagon-Like Peptide-1 Receptor
Proteins
glucagon-like peptide 1 (7-37)

Keywords

  • Allosteric Regulation
  • Amino Acid Substitution
  • Animals
  • CHO Cells
  • Calcium
  • Cricetulus
  • Cyclic AMP
  • Extracellular Space
  • Glucagon-Like Peptide 1
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mutation
  • Peptide Fragments
  • Phosphorylation
  • Polymorphism, Single Nucleotide
  • Receptors, Glucagon
  • Signal Transduction
  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this

Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery. / Koole, Cassandra; Wootten, Denise; Simms, John; Miller, Laurence J; Christopoulos, Arthur; Sexton, Patrick M.

In: The Journal of pharmacology and experimental therapeutics, Vol. 353, No. 1, 04.2015, p. 52-63.

Research output: Contribution to journalArticle

Koole, Cassandra ; Wootten, Denise ; Simms, John ; Miller, Laurence J ; Christopoulos, Arthur ; Sexton, Patrick M. / Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery. In: The Journal of pharmacology and experimental therapeutics. 2015 ; Vol. 353, No. 1. pp. 52-63.
@article{ab89f38ad3a143cfa887deabd6e6eb2f,
title = "Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery",
abstract = "The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that has a critical role in the regulation of glucose homeostasis, principally through the regulation of insulin secretion. The receptor system is highly complex, able to be activated by both endogenous [GLP-1(1-36)NH2, GLP-1(1-37), GLP-1(7-36)NH2, GLP-1(7-37), oxyntomodulin], and exogenous (exendin-4) peptides in addition to small-molecule allosteric agonists (compound 2 [6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline], BETP [4-(3-benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine]). Furthermore, the GLP-1R is subject to single-nucleotide polymorphic variance, resulting in amino acid changes in the receptor protein. In this study, we investigated two polymorphic variants previously reported to impact peptide-mediated receptor activity (M149) and small-molecule allostery (C333). These residues were mutated to a series of alternate amino acids, and their functionality was monitored across physiologically significant signaling pathways, including cAMP, extracellular signal-regulated kinase 1 and 2 phosphorylation, and intracellular Ca(2+) mobilization, in addition to peptide binding and cell-surface expression. We observed that residue 149 is highly sensitive to mutation, with almost all peptide responses significantly attenuated at mutated receptors. However, most reductions in activity were able to be restored by the small-molecule allosteric agonist compound 2. Conversely, mutation of residue 333 had little impact on peptide-mediated receptor activation, but this activity could not be modulated by compound 2 to the same extent as that observed at the wild-type receptor. These results provide insight into the importance of residues 149 and 333 in peptide function and highlight the complexities of allosteric modulation within this receptor system.",
keywords = "Allosteric Regulation, Amino Acid Substitution, Animals, CHO Cells, Calcium, Cricetulus, Cyclic AMP, Extracellular Space, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Humans, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Mutation, Peptide Fragments, Phosphorylation, Polymorphism, Single Nucleotide, Receptors, Glucagon, Signal Transduction, Journal Article, Research Support, Non-U.S. Gov't",
author = "Cassandra Koole and Denise Wootten and John Simms and Miller, {Laurence J} and Arthur Christopoulos and Sexton, {Patrick M}",
note = "Copyright {\circledC} 2015 by The American Society for Pharmacology and Experimental Therapeutics.",
year = "2015",
month = "4",
doi = "10.1124/jpet.114.220913",
language = "English",
volume = "353",
pages = "52--63",
journal = "The Journal of pharmacology and experimental therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery

AU - Koole, Cassandra

AU - Wootten, Denise

AU - Simms, John

AU - Miller, Laurence J

AU - Christopoulos, Arthur

AU - Sexton, Patrick M

N1 - Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

PY - 2015/4

Y1 - 2015/4

N2 - The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that has a critical role in the regulation of glucose homeostasis, principally through the regulation of insulin secretion. The receptor system is highly complex, able to be activated by both endogenous [GLP-1(1-36)NH2, GLP-1(1-37), GLP-1(7-36)NH2, GLP-1(7-37), oxyntomodulin], and exogenous (exendin-4) peptides in addition to small-molecule allosteric agonists (compound 2 [6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline], BETP [4-(3-benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine]). Furthermore, the GLP-1R is subject to single-nucleotide polymorphic variance, resulting in amino acid changes in the receptor protein. In this study, we investigated two polymorphic variants previously reported to impact peptide-mediated receptor activity (M149) and small-molecule allostery (C333). These residues were mutated to a series of alternate amino acids, and their functionality was monitored across physiologically significant signaling pathways, including cAMP, extracellular signal-regulated kinase 1 and 2 phosphorylation, and intracellular Ca(2+) mobilization, in addition to peptide binding and cell-surface expression. We observed that residue 149 is highly sensitive to mutation, with almost all peptide responses significantly attenuated at mutated receptors. However, most reductions in activity were able to be restored by the small-molecule allosteric agonist compound 2. Conversely, mutation of residue 333 had little impact on peptide-mediated receptor activation, but this activity could not be modulated by compound 2 to the same extent as that observed at the wild-type receptor. These results provide insight into the importance of residues 149 and 333 in peptide function and highlight the complexities of allosteric modulation within this receptor system.

AB - The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that has a critical role in the regulation of glucose homeostasis, principally through the regulation of insulin secretion. The receptor system is highly complex, able to be activated by both endogenous [GLP-1(1-36)NH2, GLP-1(1-37), GLP-1(7-36)NH2, GLP-1(7-37), oxyntomodulin], and exogenous (exendin-4) peptides in addition to small-molecule allosteric agonists (compound 2 [6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline], BETP [4-(3-benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine]). Furthermore, the GLP-1R is subject to single-nucleotide polymorphic variance, resulting in amino acid changes in the receptor protein. In this study, we investigated two polymorphic variants previously reported to impact peptide-mediated receptor activity (M149) and small-molecule allostery (C333). These residues were mutated to a series of alternate amino acids, and their functionality was monitored across physiologically significant signaling pathways, including cAMP, extracellular signal-regulated kinase 1 and 2 phosphorylation, and intracellular Ca(2+) mobilization, in addition to peptide binding and cell-surface expression. We observed that residue 149 is highly sensitive to mutation, with almost all peptide responses significantly attenuated at mutated receptors. However, most reductions in activity were able to be restored by the small-molecule allosteric agonist compound 2. Conversely, mutation of residue 333 had little impact on peptide-mediated receptor activation, but this activity could not be modulated by compound 2 to the same extent as that observed at the wild-type receptor. These results provide insight into the importance of residues 149 and 333 in peptide function and highlight the complexities of allosteric modulation within this receptor system.

KW - Allosteric Regulation

KW - Amino Acid Substitution

KW - Animals

KW - CHO Cells

KW - Calcium

KW - Cricetulus

KW - Cyclic AMP

KW - Extracellular Space

KW - Glucagon-Like Peptide 1

KW - Glucagon-Like Peptide-1 Receptor

KW - Humans

KW - Mitogen-Activated Protein Kinase 1

KW - Mitogen-Activated Protein Kinase 3

KW - Mutation

KW - Peptide Fragments

KW - Phosphorylation

KW - Polymorphism, Single Nucleotide

KW - Receptors, Glucagon

KW - Signal Transduction

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1124/jpet.114.220913

DO - 10.1124/jpet.114.220913

M3 - Article

VL - 353

SP - 52

EP - 63

JO - The Journal of pharmacology and experimental therapeutics

JF - The Journal of pharmacology and experimental therapeutics

SN - 0022-3565

IS - 1

ER -